Effectiveness of Oral Albendazole in the Treatment of Severe Acute Malnutrition
Overview
The benefit of anti-worm therapy as part of the case management of severe acute malnutrition (SAM) in the outpatient setting has not previously been studied. This study will compare recovery rates of children with SAM treated in the community with locally-produced ready-to-use therapeutic food (RUTF) with and without prescribed albendazole as part of their case management.
Full Title of Study: “Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Benefit of Antihelminthic Therapy in the Community-Based Treatment of Severe Acute Malnutrition in Malawian Children”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Study Primary Completion Date: January 2014
Interventions
- Drug: Placebo
- placebo given once
- Drug: Albendazole
- single dose albendazole given at the time of enrollment
Arms, Groups and Cohorts
- Placebo Comparator: Placebo
- Experimental: Albendazole
Clinical Trial Outcome Measures
Primary Measures
- nutritional recovery
- Time Frame: 12 weeks
- Weight-for-Height Z-score (WHZ) > -2 without bipedal pitting edema
- mortality
- Time Frame: 12 weeks
Secondary Measures
- malnutrition relapse
- Time Frame: 6 months
- acute malnutrition, either moderate (WHZ < -2) or severe (WHZ < -3 and/or bipedal pitting edema)
- height and weight gain
- Time Frame: 6 months
Participating in This Clinical Trial
Inclusion Criteria
- 12-59 months old – Kwashiorkor and/or Marasmus – Qualified for home-based therapeutic feeding with RUTF Exclusion Criteria:
- Obvious congenital or other malformation that makes child a poor candidate for feeding with RUTF – Unable to consume test-dose of RUTF in clinic – Parent refusal to participate and return for follow-up
Gender Eligibility: All
Minimum Age: 6 Months
Maximum Age: 59 Months
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Washington University School of Medicine
- Collaborator
- Kamuzu University of Health Sciences
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Mark J Manary, MD, Principal Investigator, University of Malawi
- Kenneth Maleta, MBBS PhD, Principal Investigator, University of Malawi
- Indi Trehan, MD MPH DTM&H, Study Director, University of Malawi
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.